REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Affiliation auteursAffiliation ok
TitreREMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
Type de publicationJournal Article
Year of Publication2017
AuteursLepage C., Dahan L., Legoux J.L, Le Malicot K., Guimbaud R., Tougeron D., Lievre A., Bouarioua N., Petorin C., Pavel M., Borbath I, Toumpanakis C., Smith D., Ducreux M., Walter T.
JournalNEUROENDOCRINOLOGY
Volume105
Pagination187
Type of ArticleMeeting Abstract
ISSN0028-3835
Mots-clésClinical trial, duodeno-pancreatic neuroendocrine tumours, Maintenance